SEC Tracker
Get the app

Oyster Point Pharma

Oyster Point Pharma says George Eliades resigned from the board

Form
8-K/A
Filed
Importance
Routine
  • Ends a material agreement (1.02)
  • Completes an acquisition or sale of assets (2.01)
  • Reports an exchange listing deficiency notice (3.01)
  • Changes shareholder rights (3.03)
  • Reports a change in control (5.01)
  • Reports an executive or board change (5.02)
  • Amends its charter or bylaws (5.03)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Oyster Point Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float not reported.

  1. Adaptimmune Therapeutics ADAP
  2. Adverum Biotechnologies ADVM
  3. AgomAb Therapeutics AGMB
  4. Alvotech ALVO
  5. Argenx ARGX

Data on this page was fetched . The filing on SEC.gov is the record.